Levi & Korsinsky Investigates Fairness of Revance Therapeutics’ Acquisition by Crown Laboratories
New York, NY – February 24, 2025
Levi & Korsinsky, LLP announces that it has commenced an investigation into the fairness of the acquisition of Revance Therapeutics Inc (“RVNC” or the “Company”) by Crown Laboratories, Inc. (“Crown”). This investigation follows a February 15, 2025, announcement that Crown would acquire Revance for approximately $2.1 billion in cash.
Impact on Revance Therapeutics Shareholders
The investigation concerns whether the Board of Directors of Revance Therapeutics breached their fiduciary duties by selling the Company to Crown Laboratories for an inadequate consideration. If you are a Revance Therapeutics stockholder and purchased Revance securities prior to August 11, 2024, you may be entitled to compensation.
Potential Global Implications
This investigation has potential implications for the biotech industry as a whole. The acquisition of Revance Therapeutics by Crown Laboratories represents a significant move in the competitive landscape of the industry. The fairness of the transaction will be closely watched by other companies, investors, and regulatory bodies.
Revance Therapeutics is a clinical-stage biotech company that focuses on developing and commercializing innovative treatments for aesthetics and neurological disorders. The Company’s lead product candidate, DAXI, is a potential game-changer in the aesthetics market, offering longer-lasting effects than current treatments. Crown Laboratories, on the other hand, is a specialty pharmaceutical company with a diversified portfolio of prescription and over-the-counter products.
The acquisition of Revance Therapeutics by Crown Laboratories will bring DAXI and other potential treatments under the Crown umbrella. This could lead to increased competition in the aesthetics market and potentially disrupt the current market dynamics.
- Increased competition in the aesthetics market
- Potential disruption of current market dynamics
- Impact on other biotech companies and their M&A strategies
Next Steps for Affected Shareholders
If you are a Revance Therapeutics stockholder and wish to learn more about the investigation or potential remedies, you may, without obligation or cost to you, contact Levi & Korsinsky, LLP at (212) 363-7500. You may also visit the firm’s website at www.zlk.com to learn more about the firm and the investigation.
Levi & Korsinsky, LLP has significant expertise in securities litigation and has recovered hundreds of millions of dollars for aggrieved shareholders. The firm is committed to ensuring that all corporations and their officers and directors operate in the fullest compliance with both the letter and spirit of the law.
Conclusion
The acquisition of Revance Therapeutics by Crown Laboratories has significant implications for both the biotech industry and Revance Therapeutics shareholders. Levi & Korsinsky, LLP’s investigation into the fairness of the transaction will closely examine the potential breach of fiduciary duties by the Revance Board of Directors. The outcome of the investigation could lead to potential compensation for affected shareholders and provide valuable insights into M&A strategies in the biotech industry. If you are a Revance Therapeutics shareholder, contact Levi & Korsinsky, LLP to learn more about your potential rights and remedies.
For more information, please visit www.zlk.com or contact Levi & Korsinsky, LLP at (212) 363-7500.
Levi & Korsinsky, LLP
30 Broad Street – 24th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500
Fax: (212) 363-7171
SOURCE Levi & Korsinsky, LLP
// END //
